BridgeBio Pharma Inc (STU:2CL)
€ 59.51 +0.11 (+0.19%) Market Cap: 11.57 Bil Enterprise Value: 13.12 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 65/100

BridgeBio Pharma, Inc. at Morgan Stanley Global Healthcare Conference Transcript

Sep 15, 2026 / 02:00PM GMT
Release Date Price: €59.4 (-5.26%)
Sean Laaman
Morgan Stanley - Analyst

Good morning, everyone. I'm Sean Laaman, Head of US Mid-cap Biotech Equity Research here at Morgan Stanley, and welcome to the Morgan Stanley Global Healthcare Conference. Before we commence, I'll make you aware of some important disclosures. For those disclosures, please visit the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have the pleasure of hosting Bridge Biopharma with Julie Everett, COO of BridgeBio Skeletal Dysplasia and Chief Business Officer, Chinmay Shukla. Welcome to both of you, and thank you for your time today.

Questions & Answers

Sean Laaman
Morgan Stanley - Analyst

I've got some macro considerations. We're just talking about interest rates offline, but just some macro considerations to discuss before we really dig in on Bridge. But how is the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot